文献速递产科母胎医学

孕前开始联合补充肌醇、益生菌和微量营养素后的围产期结局:NiPPeR随机对照试验

Peripartum outcomes after combined myo-inositol, probiotics, and micronutrient supplementation from preconception: the NiPPeR randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-08-13

NiPPeR双盲随机对照试验纳入英国、新加坡和新西兰1729名计划妊娠女性,比较孕前至孕期联合补充肌醇、益生菌和微量营养素与标准微量营养素对照的围产期结局。在589名单胎妊娠超过24周的女性中,干预组第二产程缩短20%,第二产程进展延迟的手术产风险降低(调整RR 0.61),估计失血量减少10%。

要点

  • 干预组第二产程较对照组缩短20%(调整均差-12.0分钟,95%CI -22.2至-1.2,P=.029)。
  • 干预组因第二产程进展延迟的手术产风险降低(调整RR 0.61,95%CI 0.48-0.95,P=.022)。
  • 干预组估计失血量较对照组减少10%(调整均差-35.0 mL,95%CI -70.0至-3.5,P=.047)。

核心结论

  • 孕前开始并持续至孕期的联合补充肌醇、益生菌和微量营养素可缩短第二产程、降低因第二产程延迟的手术产风险并减少分娩时失血量。

研究设计与样本

  • 双盲随机对照试验,从英国、新加坡和新西兰招募1729名18至38岁、计划于2015至2017年间受孕的女性。
  • 比较孕前及整个孕期联合补充肌醇、益生菌和微量营养素与标准微量营养素对照对围产期事件的影响,采用多项、泊松和线性回归调整研究中心、种族及重要协变量。
  • 共589名单胎妊娠超过24周的女性纳入分析,其中583名(99%)提供围产期数据,干预组293名,对照组290名。

主要发现

  • 干预组与对照组在引产率、产程中缩宫素加强、器械助产、会阴创伤及产程中剖宫产率方面无差异。
  • 第一产程时长相似,但第二产程干预组较对照组缩短20%(调整均差-12.0分钟,95%CI -22.2至-1.2,P=.029)。
  • 因第二产程进展延迟的手术产风险干预组较对照组降低(调整RR 0.61,95%CI 0.48-0.95,P=.022)。
  • 估计失血量干预组较对照组减少10%(调整均差-35.0 mL,95%CI -70.0至-3.5,P=.047),与此前减少产后出血的发现一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence that nutritional supplementation before and during pregnancy improves peripartum outcomes is sparse. In the Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health (NiPPeR) trial, we previously reported that a combined myo-inositol, probiotics, and micronutrient supplement started at preconception showed no difference in the primary outcome of gestational glycemia, but did reduce the risk of preterm delivery, preterm prelabor rupture of membranes, and major postpartum hemorrhage. OBJECTIVE: This study aimed to examine the hypothesis that a reduction in major postpartum hemorrhage following a combined nutritional (myo-inositol, probiotics, and micronutrients) intervention is linked with promotion of labor progress and reduced operative delivery. STUDY DESIGN: This double-blind randomized controlled trial recruited 1729 women from the United Kingdom, Singapore, and New Zealand, aged 18 to 38 years, and planning conception between 2015 and 2017. The effects of the nutritional intervention compared with those of a standard micronutrient supplement (control), taken at preconception and throughout pregnancy, were examined for the secondary outcomes of peripartum events using multinomial, Poisson, and linear regression adjusting for site, ethnicity, and important covariates. RESULTS: Of the women who conceived and progressed beyond 24 weeks' gestation with a singleton pregnancy (n=589), 583 (99%) provided peripartum data. Between women in the intervention (n=293) and control (n=290) groups, there were no differences in rates of labor induction, oxytocin augmentation during labor, instrumental delivery, perineal trauma, and intrapartum cesarean delivery. Although duration of the first stage of labor was similar, the second-stage duration was 20% shorter in the intervention than in the control group (adjusted mean difference, -12.0 [95% confidence interval, -22.2 to -1.2] minutes; P=.029), accompanied by a reduction in operative delivery for delayed second-stage progress (adjusted risk ratio, 0.61 [0.48-0.95]; P=.022). Estimated blood loss was 10% lower in the intervention than in the control group (adjusted mean difference, -35.0 [-70.0 to -3.5] mL; P=.047), consistent with previous findings of reduced postpartum hemorrhage. CONCLUSION: Supplementation with a specific combination of myo-inositol, probiotics, and micronutrients started at preconception and continued in pregnancy reduced the duration of the second stage of labor, the risk of operative delivery for delay in the second stage, and blood loss at delivery.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Chan SY, Yong HEJ, Chang HF, et al. Peripartum outcomes after combined myo-inositol, probiotics, and micronutrient supplementation from preconception: the NiPPeR randomized controlled trial. Am J Obstet Gynecol MFM. 2022. PMID: 35970494. doi:10.1016/j.ajogmf.2022.100714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。